Accropeutics Bioscience, a China-based clinical-stage biotech company, announced on Wednesday that the company has received approval from the Australian Human Research Ethics Committee (HREC) to launch a clinical phase I trial of its oral small molecule TYK2/JAK1 inhibitor AC-201 in Australia.
The trial, a randomised, double-blind, placebo-controlled, single and multiple ascending dose study, is to assess the safety, tolerability, pharmacokinetics, and food impacts of AC-201 in healthy adults.
AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have indicated that the product effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1, stabilising the self-inhibitory conformation of the pseudo kinase domain on the kinase domain, thereby inhibiting the function of TYK2/JAK1 kinase. It showcased significant efficacy in multiple animal models of diseases, including psoriasis, and is aimed at the treatment of psoriasis and other inflammatory and autoimmune diseases. The company said that it is expected to provide convenience and efficacy with good safety for psoriasis patients.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca